PUBLISHER: The Business Research Company | PRODUCT CODE: 1829387
PUBLISHER: The Business Research Company | PRODUCT CODE: 1829387
A uterine fibroid embolization device is a medical device used in the treatment of noncancerous tumors, specifically uterine fibroids, through a minimally invasive procedure. Uterine fibroids are benign growths in the uterus, and this device functions by restricting the blood supply to these fibroids, causing them to shrink and ultimately disappear.
The main types of technologies associated with uterine fibroid embolization devices include surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques involve specific methods and procedures employed by medical professionals. These devices are utilized in various treatment modes, including invasive, minimally invasive, and non-invasive treatments. Additionally, they find application in diverse healthcare settings such as hospitals, clinics, and ambulatory surgical centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The uterine fibroid embolization device market research report is one of a series of new reports from The Business Research Company that provides uterine fibroid embolization device market statistics, including uterine fibroid embolization device industry global market size, regional shares, competitors with a uterine fibroid embolization device market share, detailed uterine fibroid embolization device market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid embolization device industry. This uterine fibroid embolization device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The uterine fibroid embolization device market size has grown steadily in recent years. It will grow from $5.62 billion in 2024 to $5.89 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to increasing incidence of uterine fibroids, preference for non-surgical alternatives, awareness and education initiatives, focus on women's health, shift towards outpatient procedures, physician training programs.
The uterine fibroid embolization device market size is expected to see steady growth in the next few years. It will grow to $6.96 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing awareness of non-invasive treatments, global expansion of healthcare services, rise in female healthcare initiatives, integration with multidisciplinary care, expansion of outpatient services. Major trends in the forecast period include increasing adoption of minimally invasive procedures, advancements in embolic agents, personalized treatment approaches, focus on outpatient ufe procedures, integration of imaging technologies, research on bioresorbable embolic agents.
The forecast of 4.3% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for calibrated embolic particles and microcatheter delivery systems, sourced from key regions such as Belgium and the United Kingdom, could lead to treatment delays for fibroid patients.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing demand for minimally invasive surgeries is expected to drive the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve using small incisions or natural body openings to access and treat internal organs, tissues, or structures, minimizing trauma to the patient's body. Uterine fibroid embolization devices play a crucial role in these procedures by effectively treating uterine fibroids while keeping invasiveness to a minimum. These specialized devices are designed to use small incisions, reducing the impact on surrounding tissues, and catering to the rising preference for less invasive medical treatments, ultimately improving patient outcomes. For example, in August 2023, The Aesthetic Society, a US-based organization in plastic surgery and cosmetic medicine, reported that Americans spent over $11.8 billion on aesthetic procedures, marking a 2% increase from the previous year. Thus, the growing demand for minimally invasive surgeries is driving the expansion of the uterine fibroid embolization device market.
The growing aging population is also expected to contribute to the expansion of the uterine fibroid embolization devices market. The aging population, representing individuals aged 65 years and older, benefits from uterine fibroid embolization devices as a minimally invasive alternative to surgery for addressing symptomatic fibroids. This demographic experiences relief from symptoms such as excessive bleeding and pelvic pain through these devices. According to the World Health Organization's October 2022 report, the global population aged 60 years and older reached 1.4 billion in 2022, and by 2050, it is projected to double to 2.1 billion. Therefore, the increasing aging population acts as a driver for the uterine fibroid embolization devices market.
Major companies in the uterine fibroid embolization device market are focusing on developing innovative products such as the TruClear system to address the growing demand for minimally invasive treatments for uterine fibroids, aiming to enhance safety and efficacy. The TruClear system, launched by Medtronic Private Limited in November 2022, is a mechanical hysteroscopic tissue removal system used for treating intrauterine abnormalities. It features a flexible catheter inserted through the cervix into the uterus, incorporating a spinning nitinol wire loop, continuous inflow and outflow, integrated suction, and high-definition imaging, contributing to the precision and safety of uterine fibroid treatment.
In October 2024, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. Through this acquisition, Hologic seeks to expand its range of minimally invasive treatment options for women's health, with a focus on managing uterine fibroids and heavy menstrual bleeding. Gynesonics Inc. is a US-based medical technology company specializing in the development of minimally invasive solutions for treating symptomatic uterine fibroids.
Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation
North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the uterine fibroid embolization device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The uterine fibroid embolization device market consists of revenues earned by entities by provide services such as minimally invasive procedures, non-invasive procedures, minimally invasive procedures, radiofrequency ablation, medication and hormonal therapy, and embolization procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The uterine fibroid embolization device market also includes sales of medications, hysteroscopic devices, laparoscopic devices, radiofrequency ablation devices, endometrial ablation devices, hysterectomy devices, and robotic surgical systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Uterine Fibroid Embolization Device Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on uterine fibroid embolization device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for uterine fibroid embolization device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The uterine fibroid embolization device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.